News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 28, 2024

Examining Trial Data on Omaveloxolone Efficacy

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

Episodes in this series

This series features 1 kol.

EP. 1 Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

This series features 1 kol.

EP. 2 Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

This series features 1 kol.

EP. 3 Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

This series features 1 kol.

EP. 4 Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

This series features 1 kol.

EP. 5 Examining Trial Data on Omaveloxolone Efficacy

This series features 1 kol.

EP. 6 Promising Therapy Approaches for Advanced Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 7 Friedreich Ataxia: Looking Forward at the Treatment Landscape

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 8 Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 9 Diagnosis of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 10 Impact of Friedreich Ataxia on Quality of Life

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 11 Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 12 Comorbidities and Complications Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 13 Challenges Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 14 Future Considerations for Friedreich Ataxia

In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

2 experts are featured in this video

Hepatitis B Epidemiology: Closing the Screening and Diagnosis Gap

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

Experts featured in this series.

Tafasitamab Plus R² in the Community: Familiarity, Adoption, and the Shift Toward Personalized Second-Line Care

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 13th 2026

Class Switching Outcomes in RA: Key Findings From the SELECT-SWITCH Trial

ByJulia Buchfuhrer, DO

August 13th 2026

2 experts are featured in this video

Understanding the Immune Pathophysiology Driving Chronic Hepatitis B

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

Comparing JAK Inhibitor Mechanisms of Action in RA Treatment

ByJulia Buchfuhrer, DO

August 13th 2026

Trending on AJMC

CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care

Trump Childhood Vaccine Order: What It Means for Parents and Payers

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs

Employers With Claims Data Access Take More Cost Action, Survey Finds